Clinical Trials and Research

AbstractIntroductionTafamidis is the cornerstone therapy for transthyretin amyloid cardiomyopathy (ATTR–CM); however, validated criteria for monitoring disease…

Investigational PET tracer Iodine 124 Evuzamitide from Bayer meets primary endpoints in Phase III study in patients suspected to have cardiac amyloidosisMay 7…

BERLIN & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by…

AbstractAmyloidosis, characterized by the deposition of abnormal protein fibrils in organs, is classified as systemic or localized. Amyloid light chain (AL)-type…

Three patients with light chain amyloidosis have been treated with CAR T cell therapy in the first European clinical trial testing the safety and efficacy of this…

Use of the approved therapy Wainua (eplontersen) effectively slows disease progression and improves quality of life among adults with hereditary transthyretin…

AbstractBackgroundTransthyretin cardiac amyloidosis (ATTR–CM) is an increasingly recognised cause of heart failure in older adults, but real–world data in patients…

AbstractBackgroundTransthyretin amyloidosis (ATTR) is a degenerative disease affecting the heart and other organs. Transthyretin (TTR) aggregation is a driver of…

AbstractCardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by…

Study OverviewBrief SummaryThis study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac…